Salt-Sensitive Hypertension After Exposure to Angiotensin Is Associated With Inability to Upregulate Renal Epoxygenases

Hypertension

Volumn 42, Issue 4, 2003, Pages 775-780

  Zhao, Xueying ^a   Pollock, David M ^a   Zeldin, Darryl C ^a   Imig, John D ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Angiotensin II; Endothelium derived factors; Hypertension, sodium dependent; Kidney; Vessels

Indexed keywords

ALBUMIN; ANGIOTENSIN; CYTOCHROME P450; CYTOCHROME P450 2C11; CYTOCHROME P450 2C23; EPOXYGENASE; KIDNEY ENZYME; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; DIET; DOWN REGULATION; HYPERTENSION; KIDNEY BLOOD VESSEL; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOOD PRESSURE; CYTOCHROME P-450 ENZYME SYSTEM; HYPERTENSION; KIDNEY; MALE; MICROCIRCULATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SODIUM CHLORIDE; STEROID 16-ALPHA-HYDROXYLASE; UP-REGULATION;

EID: 0141997292     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.0000085649.28268.DF     Document Type: Article

References (30)

1. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996; 78: 415-423.
2. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol. 1996; 7: 2364-2370.
3. Imig JD, Falck JR, Inscho EW. Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br J Pharmacol. 1999; 127: 1399-1405.
4. Campbell WB, Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res. 1999; 84: 484-488.
5. Fang X, Kaduce TL, Weintraub NL, VanRollins M, Spector AA. Functional implications of a newly characterized pathway of 11, 12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res. 1996; 79: 784-793.
6. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Flemine I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999; 401: 493-497.
7. + exchange and are mitogenic in cultured rat glomerular mesangial cells. J Cell Physiol. 1990; 144: 429-437.
8. Zhang Y, Oltman CL, Lu T, Lee HC, Dellsperger KC, VanRollins M. EET homologs potently dilate coronary microvessels and activate BK(Ca) channels. Am J Physiol Heart Circ Physiol. 2001; 280: H2430-H2440.
9. Weintraub NL, Fang X, Kaduce TL, VanRollins M, Chatterjee P, Spector AA. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res. 1997; 81: 258-267.
10. Capdevila JH, Wei S, Yan J, Karara A, Jacobson HR, Falck JR, Guengerich FP, DuBois RN. Cytochrome P-450 arachidonic acid epoxygenase: regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem. 1992; 267: 21720-21726.
11. Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest. 1999; 104: 751-760.
12. Ma J, Qu W, Scarborough PE, Tomer KB, Moomaw CR, Maronpot R, Davis LS, Breyer MD, Zeldin DC. Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney. J Biol Chem. 1999; 274: 17777-17788.
13. Yu Z, Huse LM, Adler P, Graham L, Ma J, Zeldin DC, Kroetz DL. Increased CYP2J expression and epoxyeicosatrienoic acid formation in spontaneously hypertensive rat kidney. Mol Pharmacol. 2000; 57: 1011-1020.
14. Weir MR. Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. Am J Med. 1991; 90: 32S-36S.
15. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001; 37: 429-432.
16. Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ. Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension. 1999; 33: 1012-1019.
17. Franco M, Tapia E, Santamaria J, Zafra I, Garcia-Torres R, Gordon Pons H, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Renal cortical vasoconstriction contributes to development of sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol. 2001; 12: 2263-2271.
18. Oyekan AO, Youseff T, Fulton D, Quilley J, McGiff JC. Renal cytochrome P450 ω-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest. 1999; 104: 1131-1137.
19. Stec DE, Trolliet MR, Krieger JE, Jacob HJ, Roman RJ. Renal cytochrome P4504A activity and salt sensitivity in spontaneously hypertensive rats. Hypertension. 1996; 27: 1329-1336.
20. Monneret G, Sassard J, Benzoni D. Renal effects of cP450 arachidonate metabolites in the Lyon hypertensive rat. Fundam Clin Pharmacol. 1999; 13: 226-231.
21. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension. 2003; 41: 709-714.
22. Abraham G, Simon G. Autopotentiation of pressor responses by subpressor angiotensin II in rats. Am J Hypertens. 1994; 7: 269-275.
23. Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH. Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J Hypertens. 2001; 19: 983-992.
24. Imig JD, Zou AP, Stec DE, Harder DR, Falck JR, Roman RJ. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol. 1996; 270: R217-R227.
25. Tsao CC, Coulter SJ, Chien A, Luo G, Clayton NP, Maronpot R, Goldstein JA, Zeldin DC. Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to region-and stereoselective products. J Pharmacol Exp Ther. 2001; 299: 39-47.
26. Kaergel E, Muller DN, Honeck H, Theuer J, Shagdarsuren E, Mullally A, Luft FC, Schunck W. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension. 2002; 40: 273-279.
27. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem. 2001; 276: 36059-36062.
28. Scarborough PE, Ma J, Qu W, Zeldin DC. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab Rev. 1999; 31: 205-234.
29. Zeldin DC, Ma J, Wu S. CYP2J subfamily P450s: Physiologically relevant hemoproteins active in the epoxidation of arachidonic acid in hepatic and extrahepatic tissues. Rev Toxicol. 1997; 1: 1-32.
30. Capdevila JH, Falck JR. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophy Res Commun. 2001; 285: 571-576.